Version July 2025
EEG: electroencephalography; IV: intravenous; PLP: pyridoxal 5'-phosphate; PNPO: pyridoxamine 5'-phosphate oxidase.
* Risk of apnea, particularly when pyridoxine is given IV.
¶ Repeated every 5 to 15 minutes up to a maximum of 500 mg with continuous EEG monitoring.
Δ Obtain genetics consultation if genetic analysis is nondiagnostic.
◊ Obtain genetics consultation if genetic analysis is nondiagnostic. If molecular genetic analysis unavailable, can confirm by significantly reduced sulfite oxidase enzyme activity in cultured fibroblasts.